Skip navigation

News

Business Weeklywww.businessweekly.co.uk

Cabume - www.cabume.co.uk

Cambridge Business Magazinehttp://www.cambridge-magazines.co.uk/Cambridge-Business-Magazine/

Cell Line Models and Media for Difficult to Culture Tumor Types

AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist. More »
16 February 2017

STEMCELL Technologies Opens New Office and Laboratories in Cambridge, UK

STEMCELL Technologies UK has recently celebrated the grand opening of their Cambridge-based facility. Founded by Dr. Allen Eaves, STEMCELL provides specialized reagents and tools that support research on cancer and other diseases, as well as cell therapy and regenerative medicine globally More »
16 February 2017

Horizon Discovery Signs a Master Service Agreement with a Top Three Pharmaceutical Company

Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery and development efforts to Horizon’s full suite of services. More »
15 February 2017

Springtime for Learning and Development

Get ready to clean-up professionally with new workshops and courses from Cambridge Network's Learning Collaboration More »
14 February 2017

Biosys Appoints Axel Wiest to Board of Directors

Biosys UK Limited (“Biosys” or the “Company”), a clinical-stage microbiome company dedicated to the development of targeted oral immune therapies that modulate the gut microbiome, initially focused on the treatment of C.difficile infection (“CDI”), is pleased to announce that Axel Wiest, M.D., Ph.D., M.P.H., has joined the board of the Company. More »
14 February 2017

Horizon Discovery Signs a Master Service Agreement with a Top Three Pharmaceutical Company

Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery and development efforts to Horizon’s full suite of services. More »
14 February 2017

Imanova Appoints Preclinical Business Development Manager

Imanova continues to grow its preclinical offering, to respond to an increased demand from the pharmaceutical market, and is pleased to announce the appointment of a new Preclinical Business Development Manager, Julian Westerman. More »
14 February 2017

Owlstone Medical Commences 1,400 Patient Clinical Trial for Early Detection of Colorectal Cancer

World’s largest breath-based study into colorectal (bowel) cancer will be run in collaboration with the University of Warwick and the University Hospital Coventry and Warwickshire NHS Trust More »
13 February 2017

ONE NUCLEUS ANNOUNCES NEW DIRECTOR

Industry expert to support award winning membership organisation More »
13 February 2017

Selcia, Cypralis and Gilead Publish Synthetic Macrocyclic Cyclophilin Inhibitors Inspired by Natural Product Sanglifehrin A

Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have published in the Journal of Medicinal Chemistry a novel strategy of structural simplification of a natural product to generate synthetically tractable cyclophilin inhibitors for the treatment of HCV. More »
10 February 2017

<< Previous   Page 2 of 49   Next >>